Retrospective Study of Outcomes in Hyalgan®-Treated Patients with Osteoarthritis of the Knee
- 71 Downloads
Objective: To evaluate therapeutic success [defined as lack of total knee replacement surgery (TKR) or other significant clinical intervention during a 6-month follow-up] and to identify baseline patient and disease characteristics associated with improved pain relief and quality of life (QOL) in patients in a clinical practice who were treated with a single course of Hyalgan® (intra-articular hyaluronan) for pain associated with osteoarthritis (OA) of the knee.
Design and setting: This was an uncontrolled, retrospective study conducted at a single US clinical orthopaedic practice.
Patients: 248 patients with moderate to severe OA of the knee.
Intervention: All patients received a single course of intra-articular Hyalgan® therapy during an 18-month period, and had a radiogram of the treated knee within the 6 months before treatment.
Results: A total of 218 of 363 (60.1%) knees (248 patients) with moderate to severe OA were judged successfully treated over a 6-month follow-up period; only 20.3% of cases required TKR. On the basis of a multivariate analysis that correlated improvements in pain and QOL assessed by a retrospective questionnaire with baseline patient and disease characteristics, taller patients (>165cm), patients with less severe OA, and patients with patellofemoral compartment involvement had the greatest improvement in pain relief and quality of life following treatment with Hyalgan®.
Conclusions: Hyalgan® was effective in patients with moderate to severe OA, and may have delayed TKR in 80% of patients. Taller patients, patients with less severe OA, and patients with patellofemoral compartment involvement showed the greatest pain relief and improvements in QOL.
KeywordsTotal Knee Replacement Intervention Therapy Sodium Hyaluronate Contingency Table Analysis Primary Efficacy Outcome
This study was supported in part by a grant from Sanofi-Synthelabo Inc. Statistical analysis support was provided by Fidia, SpA.
- 3.Balazs EA, Denlinger JL. Viscosupplementation: anew concept in the treatment of osteoarthritis. J Rheumatol Suppl 1993; 39: 3–9Google Scholar
- 4.Synvisc® [prescribing information]. Philadelphia (PA): Wyeth-Ayerst, 2000Google Scholar
- 5.Hyalgan® [prescribing information]. New York: Sanofi Pharmaceuticals, Inc, 2000Google Scholar
- 7.Scali JJ. Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: a long term study. Eur J Rheum Inflamm 1995; 15: 57–62Google Scholar
- 11.Carrabba M, Paresce E, Angelini M, et al. The safety and efficacy of different dose schedules of hyaluronic acid in the treatment of painful osteoarthritis of the knee with joint effusion. Eur J Rheumatol Inflamm 1995; 15: 25–31Google Scholar
- 14.Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986; 29: 1039–49PubMedCrossRefGoogle Scholar
- 16.Barrett JP, Rashkoff E, Sirna EC, et al. Correlation of roentgenographic patterns and clinical manifestations of symptomatic idiopathic osteoarthritis of the knee. Clin Orthop Relat Res 1988; 253: 179–83Google Scholar
- 18.Leardini G, Franceschini M, Mattara L, et al. Intra-articular sodium hyaluronate (Hyalgan®) in gonarthrosis. Clin Trial J 1987; 24: 341–50Google Scholar
- 20.National Institutes of Health. Osteoarthritis: new insights. Part I. Ann Intern Med 2000; 133: 635–6Google Scholar